Complain about a product or service

Researchers "Closer" To Preventing Alzheimer's

July 6, 2006

• Low Levels of 'Good Cholesterol' Linked to Memory Loss, Dementia Risk • Chemical in Celery May Fight Alzheimer's • Dementia Linked To Obesity • Studies Find Link Between Diabetes and Alzheimer's • Lifestyle Linked to Alzheimer's Onset • Pot Belly in Middle Age Linked to Alzheimer's • 10 Million Boomers Face Alzheimer's • Alzheimer's Risk Higher in Victims' Children • Fast-Acting Alzheimer's Therapy Excites Researchers • Too Much Sugar May Increase Alzheimer’s Risk • Beta Carotene May Slow Memory Loss • Promising Alzheimer’s Discovery Reported • Misconceptions About Alzheimer's Vary Among Races • Mediterranean Diet May Extend Alzheimer’s Patients’ Lives • Researchers Link Smoking To Dementia • Caffeine May Keep Dementia At Bay In Women • Alzheimer’s Drug Seen As “Safe, Effective” • Researchers “A Step Closer” To Alzheimer’s Cure • FDA Approves Alzheimer’s Patch • Scientists Raise Hopes For Alzheimer's Vaccine • Researchers Hopeful About New Alzheimer’s Therapy • Blood Pressure Drugs May Provide Alzheimer’s Protection • Progress Toward Early Alzheimer's Diagnosis Reported • Alzheimer's Cases Up 10% In 5 Years • Loneliness Linked to Dementia • Gene Changes Identified in Alzheimer's • Mental Exercise May Help Seniors • Rote Learning Improves Memory in Seniors • Vegetables May Slow Memory Loss • Cabernet Sauvignon May Reduce Alzheimer's Risk • Fruit Juice May Reduce Alzheimer's Risk • Skin Test May Detect Alzheimer's Disease • Exercise May Prevent Dementia-Like Illnesses • An Apple A Day May Improve Memory • New Drug Reverses Alzheimer's Damage, Australian Researchers Report • Diabetes Drug May Help Treat Alzheimer's • For Women, Weight Loss May Precede Dementia • Researchers "Closer" To Preventing Alzheimer's • Statins Help Memory in Older Women • Study Links Healthy Diet To Reduced Alzheimer's Risk • Tea May Help Combat Alzheimer's • Education May Accelerate Alzheimer's Effects • Alzheimer's Found to be Mostly Genetic • Exercise May Reduce Risk of Dementia in Older People • Researchers Find DNA Link to Alzheimer's • Brain Scan, Fluid Analysis May Help Predict Alzheimer's • Eating Fish Associated With Slower Cognitive Decline • Word Recall An Alzheimer' s Tip-Off? • Interrupted Alzheimer's Trial Produced Promising Results • Gene Therapy May Offer Hope For Alzheimer's Patients • Alzheimer's Researchers Reverse Memory Loss in Mice • Alzheimer's Disease Reveals Itself Earlier, Study Finds

A recent study directed by Mount Sinai School of Medicine identifies a faulty molecule in the brain found in cases of mild cognitive impairment (MCI). Researchers say this faulty molecule may be responsible for the progression of MCI to mild Alzheimer's disease.

The study, which appeared June 10th online in the journal Neurobiology of Aging, may lead to preventative treatments for Alzheimer's.

An estimated 4.5 million Americans have Alzheimer's disease and presently there are no known cures or effective preventive strategies.

"Alzheimer's Disease is a growing health concern that affects millions of people," said Giulio Maria Pasinetti, M.D., Ph.D., Professor of Psychiatry and Neuroscience, Director of the Neuroinflammation Research Center at Mount Sinai School of Medicine and lead author of the study.

"We hope our research provides direction for preventative treatments to delay the onset of Alzheimer's dementia by eliminating amyloid plaque-causing peptides in the brain."

People with Alzheimer's exhibit elevated levels of beta-amyloid peptides that cause plaque buildup in the brain, the main characteristic of Alzheimer's. In the earliest stages of Alzheimer's, beta-amyloid peptides are on the rise, especially in the two connected brain regions critical for memory functions -- the hippocampus and entorhinal cortex.

In this study, Pasinetti and colleagues at Mount Sinai School of Medicine in New York suggest one reason for that early increase of beta-amyloid peptides: an enzyme that breaks down beta-amyloid peptides, also referred to as an insulin-degrading enzyme (IDE), is not active in the brain in the cases at high-risk for developing Alzheimer's.

To assess possible changes in IDE during MCI, the investigators measured protein levels and enzymatic activity in postmortem brain tissue from 46 elderly subjects.

Implications

A loss of IDE activity has been previously shown to occur in severe Alzheimer's dementia, and the current results raise the possibility that a deficit in degrAlzheimer's ation of amyloid peptides from IDE could raise levels of toxic beta-amyloid peptides even before Alzheimer's dementia is diagnosed.

If these results are confirmed, Mount Sinai researchers suggest that boosting IDE activity pharmacologically may reverse beta-amyloid peptide accumulation. This new finding may provide a pharmacological therapeutic angle to preventing Alzheimer's.

Pasinetti and colleagues also measured levels of beta-amyloid peptides in the entorhinal cortex and found that the amount of beta-amyloid was inversely correlated with IDE activity they measured in the hippocampus.

These results support the idea that alterations in IDE might be causally related to beta-amyloid peptides accumulation, starting in the earliest stages of Alzheimer's.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.